Moody Aldrich Partners LLC Tcr2 Therapeutics Inc. Transaction History

Moody Aldrich Partners LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Oct 29, 2021	SELL	$8.44 - $18.35 $1.05 Million - $2.28 Million	-124,062 Closed	0 $0
Q2 2021 Aug 04, 2021	SELL	$16.41 - $24.71 $25,894 - $38,992	-1,578 Reduced 1.26%	124,062 $2.04 Million
Q1 2021 May 10, 2021	BUY	$20.38 - $34.07 $40,780 - $68,174	2,001 Added 1.62%	125,640 $2.77 Million
Q4 2020 Feb 16, 2021	BUY	$19.0 - $32.63 $2.35 Million - $4.03 Million	123,639 New	123,639 $3.82 Million

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Moody Aldrich Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Moody Aldrich Partners LLC with notifications on news.